Xuanzhu Biopharm Co Ltd

Price Chart

Risk-Adjusted Performance

Xuanzhu Biopharm Co Ltd (2575) Price Performance

Xuanzhu Biopharm Co Ltd (2575) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at HKD33.56, up 1.94% from the previous close.

Over the past year, 2575 has traded between a low of HKD26.30 and a high of HKD82.95. The stock has gained 27.6% over this period. It is currently 59.5% below its 52-week high.

Xuanzhu Biopharm Co Ltd has a market capitalization of $18.59B.

About Xuanzhu Biopharm Co Ltd

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate, which is in Phase I clinical trial; KM602, which is in Phase I clinical trial for anti-tumor; XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 inhibitor; and XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor. In addition, it develops XZB-0004, an oral small molecule anexelekto inhibitor; XZP-6877, a DNA-dependent protein kinase inhibitor; NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroid farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. The company was founded in 2008 and is headquartered in Beijing, China. Xuanzhu Biopharmaceutical Co., Ltd. is a former subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.

Compare Xuanzhu Biopharm Co Ltd

Side-by-side comparison against top Healthcare peers.